These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1562 related articles for article (PubMed ID: 15837627)

  • 1. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Levine RL; Wadleigh M; Cools J; Ebert BL; Wernig G; Huntly BJ; Boggon TJ; Wlodarska I; Clark JJ; Moore S; Adelsperger J; Koo S; Lee JC; Gabriel S; Mercher T; D'Andrea A; Fröhling S; Döhner K; Marynen P; Vandenberghe P; Mesa RA; Tefferi A; Griffin JD; Eck MJ; Sellers WR; Meyerson M; Golub TR; Lee SJ; Gilliland DG
    Cancer Cell; 2005 Apr; 7(4):387-97. PubMed ID: 15837627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.
    Levine RL; Belisle C; Wadleigh M; Zahrieh D; Lee S; Chagnon P; Gilliland DG; Busque L
    Blood; 2006 May; 107(10):4139-41. PubMed ID: 16434490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
    Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
    Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
    Kilpivaara O; Levine RL
    Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.
    Scott LM; Scott MA; Campbell PJ; Green AR
    Blood; 2006 Oct; 108(7):2435-7. PubMed ID: 16772604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.
    Vannucchi AM; Antonioli E; Guglielmelli P; Pardanani A; Tefferi A
    Leukemia; 2008 Jul; 22(7):1299-307. PubMed ID: 18496562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case of myelofibrosis with myeloid metaplasia with JAK2(V617F) mutation who developed fibrous tumours in multiple organs.
    Tabuchi T; Ohashi H; Fukami S; Susaki N; Kunishima S; Yokozawa T; Nagai H; Moritani S; Ichihara S; Saito H; Hamaguchi M
    Eur J Haematol; 2006 Sep; 77(3):264-6. PubMed ID: 16923114
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship between the 46/1 haplotype of the JAK2 gene and the JAK2 mutational status and allele burden, the initial findings, and the survival of patients with myelofibrosis.
    Martínez-Trillos A; Maffioli M; Colomer D; Alvarez-Larrán A; Pereira A; Angona A; Bellosillo B; Cervantes F
    Ann Hematol; 2014 May; 93(5):797-802. PubMed ID: 24337516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
    Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
    Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
    Ganly P; Hanrahan V; Baker B; Romeril K
    Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
    Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
    Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.